Preclinical data on MD Anderson Cancer Center-developed drug offers hope for Imbruvica-resistant mantle cell lymphoma patients

First approved in 2013 for relapsed/refractory mantle cell lymphoma (MCL), J&J’s Imbruvica is now being used as the first line of defense for the rare, aggressive, incurable form of non-Hodgkin lymphoma.